Trending...
- CoreSite Announces First Quarter 2021 Earnings Conference Call
- Colorado Springs: Behind the Springs: What is Community Development?
- Avo Limo LLC and Spring in Colorado
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that management will participate in two upcoming conferences: the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held February 17-19, 2021, and the LifeSci Partners Precision Oncology Day, which is being held February 17, 2021.
Event Details:
About Biodesix
Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood based Nodify Lung™ nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT™ tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.
More on Colorado Desk
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "plan," "expect," "predict," "potential," "opportunity," "goals," or "should," and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix's most recent quarterly report on Form 10Q, filed December 10, 2020. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Event Details:
Event: | BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference | ||
Format: | Fireside chat | ||
Date: | Wednesday, February 17 | ||
Time: | 4:00pm ET | ||
Event: | LifeSci Partners Precision Oncology Day | ||
More on Colorado Desk
Format: | Panel discussion on diagnostic sequencing for the treatment of cancer patients | ||
Date: | Wednesday, February 17 | ||
Time: | 12:00pm ET |
About Biodesix
Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood based Nodify Lung™ nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT™ tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.
More on Colorado Desk
- Presenting Companies for the 2021 Mining Cleantech Challenge Announced
- Green Spoon Sales & Shelvspace Unveil New-To-Market Retail Software
- Gary S. Monroe, C.D. Accelerates Promising New Treatments For Cocaine And Methamphetamine Addicts
- Legendary Hall of Famer Andre Dawson welcomes golfers to charity tournament
- Colorado State Land Board Selects Hospitality at Work® to Manage Commercial Property Portfolio
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "plan," "expect," "predict," "potential," "opportunity," "goals," or "should," and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix's most recent quarterly report on Form 10Q, filed December 10, 2020. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Filed Under: Business
0 Comments
Latest on Colorado Desk
- CB Insights Again Names AI.Reverie a Top 100 AI Startup
- New Large Format Custom Print, Branding and Sourcing Company Welcomes Sports Industry Veteran as Founding Partner
- Veritone to Hold Virtual Investor Day and Technology Expo on May 14, 2021
- Terminal Railroad Association of St. Louis Implements CrewPro Short Line
- Ismail Sirdah's Helpful Tips For Selling Event Ticket Online
- Colorado Springs: Summit House demolition now underway
- Sandline Global Broadens Commitment to Data & Analytics: Adam Poeppelmeier Joins as Director of Business Intelligence
- CCIA & CALSTART Announce Call for Applications for the 2021 Commercial Vehicle Cleantech Challenge
- The Savory Grape Launches New Online Shopping And Delivery Experience
- Liberty TripAdvisor Holdings, Inc. Announces Closing of Overallotment Option in Connection with Previously Announced Private Offering of Exchangeable Senior Debentures and the Completion of its Repurchase of 42% of Preferred Stock from Certares
- If Your Pavements Could Talk, What Would They Tell You?
- Covid-19 Quarantine Spawns 18 "Pregnancy After 40" Birth Announcements From Group Members in a Single Week
- Avo Limo LLC and Spring in Colorado
- Massage Therapy Center in Los Angeles is Putting a Spring Back In Your Step
- Multi-platinum singer Linda Varg and Audilus to join forces
- Social Security The Great Ponzi Scheme: "If This Book Doesn't Raise Your Blood Pressure, You'd Better Check For A Pulse!"
- Survey Finds 2020 High School Graduates Delayed College Plans, Concerned about Financial Security
- National Minority Health Association Launches PSA to Increase Vaccine Confidence in Minority Communities
- Join Spectra Art Space Tonight! *Bringing Art Auctions To The People*
- Global Connectivity Demand Drives Zayo's Fiber Network Expansion in Florida